162 Journal of Family Planning and Reproductive Health Care 2003: 29(3) Background Inevitably there are limited long-term safety data for any new contraceptive method. Detailed scientific studies, performed in a small number of women, provide evidence on mode of action. Larger clinical trials examine efficacy, side effects and acceptability. The number of women-years of exposure is less than fo...

162 Journal of Family Planning and Reproductive Health Care 2003: 29(3) Background Inevitably there are limited long-term safety data for any new contraceptive method. Detailed scientific studies, performed in a small number of women, provide evidence on mode of action. Larger clinical trials examine efficacy, side effects and acceptability. The number of women-years of exposure is less than fo...

162 Journal of Family Planning and Reproductive Health Care 2003: 29(3) Background Inevitably there are limited long-term safety data for any new contraceptive method. Detailed scientific studies, performed in a small number of women, provide evidence on mode of action. Larger clinical trials examine efficacy, side effects and acceptability. The number of women-years of exposure is less than fo...

women discontinued due to problems with compliance to the study. Although women were not randomised, statistical tests showed both groups were similar with respect to demographic details of women and infants. The results indicated there was no significant difference in mean volume of milk produced between the two groups. Milk volume was measured as preand post-feed infant weight, over 24 hours ...

In this open-label, randomized study we compared the influence of a new oral contraceptive containing 30 microg ethinylestradiol and 3 mg drospirenone (Yasmin) with a reference preparation containing 30 microg ethinylestradiol and 150 microg desogestrel (Marvelon) on variables of carbohydrate metabolism by means of oral glucose tolerance tests at baseline and in the 6th and 13th treatment cycle...

A plausible mechanism to explain thrombotic risk differences associated with the use of second- and third-generation oral contraceptives (OCs), particularly in carriers of factor V(Leiden), is still lacking. In a double-blind trial, 51 women without and 35 women with factor V(Leiden) were randomized to either a second- (30 microg ethinylestradiol/150 microg levonorgestrel) or third- (30 microg ...

This report presents a unique case of hypercalcemia with an elusive etiology. A 37-year-old Caucasian female history gonadotropin-secreting pituitary microadenoma and recurrent nephrolithiasis was found to have hypercalcemia, hypercalciuria, elevated 1,25-dihydroxyvitamin D levels, low parathyroid hormone levels. Extensive investigations were conducted identify the cause, including ruling out s...

Public Citizen, representing more than 100,000 consumers nationwide, hereby petitlons the Food and Drug Administration (FDA) pursuant to the Federal Food, Drug and Cosmetic Act 21 U.S.C. Section 355(e)(3), and 2 1 C.F.R. 10.30, to immediately ban the third generation oral contraceptives containing desogestrel due to the approximately doubled risk of venous thrombosis (30 cases for every 100,000...

OBJECTIVE To investigate if continuation rates in first-time users of oral hormonal contraceptives differed between different formulations and to measure if the rates were related to the prescribing categories, that is, physicians and midwives. DESIGN A longitudinal national population-based registry study. SETTING The Swedish prescribed drug register. PARTICIPANTS All women born between ...

Recent concern about the safety of combined oral contraceptives (OCs) with third-generation progestagens prompted an examination of data from a population-based case-control study (Leiden Thrombophilia Study). We compared the risk of deep-vein thrombosis (DVT) during use of the newest OCs, containing a third-generation progestagen, with the risk of "older" products. We also investigated the inf...